NCT04799847 - Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Bladder Cancer

Interventions

DRUG

Catumaxomab

This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.

Trial Locations (5)

510080

RECRUITING

The First Affiliated Hospital,Sun Yat-sen University, Guangzhou

Unknown

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

RECRUITING

Peking University Third Hospital, Beijing

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin